Previous Article | Next Article ![]()
Infection and Immunity, August 2005, p. 5233-5237, Vol. 73, No. 8
0019-9567/05/$08.00+0 doi:10.1128/IAI.73.8.5233-5237.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Department of Veterinary and Biomedical Sciences, University of Minnesota, Saint Paul, Minnesota
Received 9 November 2004/ Returned for modification 30 November 2004/ Accepted 4 April 2005
|
|
|---|
|
|
|---|
and ß subunits of ß2 integrins. The amino acid residues located between positions 102 and 344 of the N-terminal region of CD18 are highly conserved among different species (5, 8, 20). Domains within the bovine and human CD18s are not well demarcated and defined, unlike those within CD11a. The objective of the present study was to map the site within bovine CD18 that is required for LktA binding and its biological effects. To accomplish this, we created several bovine x human chimeric CD18 constructs by replacing the nucleotide sequences in the cDNA encoding the amino acids in the extracellular portion of human CD18 with corresponding sequences from bovine CD18. The different chimeric bovine x human CD18 cDNA constructs were recombinantly coexpressed with bovine CD11a cDNA in a human K562 cell line that lacks endogenous ß2 integrin expression and is resistant to the effects of LktA. The resulting chimeric leukocyte function-associated antigen 1 (LFA-1) transductant cells were subjected to an LktA binding assay and two different functional assays to determine their susceptibilities to LktA. Human CD18 (in pOTB7 vector) was purchased from Invitrogen (Mammalian Gene Collection clone identification no. 3532902; Invitrogen Corp., Carlsbad, Calif.) and subcloned into an MigR1 retroviral vector (16). Bovine CD18 cDNA was provided by M. Kehrli (NADC, Ames, Iowa) and subcloned into MigR1. Bovine CD11a cDNA was generated in our laboratory (GenBank accession no. AY382558) and subcloned into a pMSCV-puro (Clontech Laboratories, Inc., Palo Alto, Calif.) retroviral vector. The chimeric constructs generated using the bovine and human CD18s are shown in Fig. 1. Each construct was generated in two steps (3, 11, 13, 14). In the first step, human or bovine CD18 sequences were amplified with high-fidelity Vent polymerase. In the second step, the isolated PCR products were used as megaprimers that were denatured and annealed to bovine CD18 in MigR1 or human CD18 in MigR1 and extended in the replacement amplification reaction. For example, to replace the N-terminal 600 amino acids of the bovine CD18 with the corresponding human sequence in H600B, the bovine cDNA sequence encoding amino acids 601 to 769 was amplified in a PCR (primers used are shown in Table 1). Each primer was designed to have complementary sequences to the bovine CD18 cDNA sequence and the human CD18 cDNA sequence. The PCR product was analyzed on 1.0% agarose gel, stained with ethidium bromide, and visualized using the EagleEye (Stratagene, Inc., La Jolla, Calif.) apparatus. The amplicon band corresponding to the expected size (0.55 kb) was excised from the agarose gel, purified using a MinElute (QIAGEN, Inc., Valencia, Calif.) gel extraction kit, and sequenced to confirm that the correct region was amplified. The purified PCR product was then used as a megaprimer in the replacement amplification of the MigR1-human-CDl8 to replace the corresponding region with the bovine sequences. All PCRs were carried out under the following conditions. For the first-round PCR, 10 µl of 10x ThermoPol reaction buffer (New England BioLabs, Inc., Beverly, Mass.), 2 µl of 10 mM deoxynucleoside triphosphate, 100 pmol primers, 100 ng template DNA, 1 µl Vent polymerase, and H2O to 100 µl were used with the following PCR conditions: 95°C for 30 seconds, 55°C for 55 seconds, and 72°C for 1 min/kb. For the second round of PCR, 50 µl of 10x Pfu ultra buffer, 1 µl of 10 mM deoxynucleoside triphosphate, 50 ng template DNA, 50 pmol of isolated PCR product from the first round, 1 µl PfuUltra high-fidelity DNA polymerase (Stratagene, Inc., La Jolla, Calif.), and H2O to 50 µl were used with the following PCR conditions: 95°C for 30 seconds, 60°C for 50 seconds, and 72°C 1 min/kb. This step was followed by DpnI digestion for 1 h to destroy the parental strand, and the construct was transformed into HL-10 Gold Ultra competent cells (Stratagene, Inc., La Jolla, Calif.) and subjected to selection on Luria-Bertani-ampicillin agar plates. Clones generated by domain swapping were then sequence verified at the Advanced Genetic Analysis Center, University of Minnesota. Sequencing results from each construct were aligned with both human CD18 and bovine CD18 using MegAlign (DNAStar, Madison, Wis.). The results indicated that all 10 constructs contained the appropriate swapped regions, with no nonspecific mutations.
![]() View larger version (33K): [in a new window] |
FIG. 1. Schematic representation of the different chimeric CD18 constructs. B110H, the N-terminal 110 amino acids of human CD18 were replaced with bovine CD18; B200H, the N-terminal 200 amino acids of human CD18 were replaced with bovine CD18; B400H, the N-terminal 400 amino acids of human CD18 were replaced with bovine CD18; B600H, the N-terminal 600 amino acids of human CD18 were replaced with bovine CD18; B700H, the entire extracellular domain of human CD18 was replaced with bovine CD18; H110B, the N-terminal 110 amino acids of bovine CD18 were replaced with human CD18; H200B, the N-terminal 200 amino acids of bovine CD18 were replaced with human CD18; H400B, the N-terminal 400 amino acids of bovine CD18 were replaced with human CD18; H500B, the N-terminal 500 amino acids of bovine CD18 were replaced with human CD18; H600B, the N-terminal 600 amino acids of bovine CD18 were replaced with human CD18. The figure also shows schematic depiction of the BoCD18 and HuCD18. aa, amino acids.
|
|
View this table: [in a new window] |
TABLE 1. Primers used for domain swappinga
|
Surface expression of chimeric CD18 dimerized with bovine CD11a in the transductants was confirmed by fluorescence-activated cell sorting (FACS) analysis using anti-bovine CD11a-specific MAb R3.1 (data not shown) and CD18-specific MAb BAQ30A (Fig. 2). BAQ30A cross-reacts with both bovine and human CD18 (data not shown). Briefly, 107 transductant cells were incubated with 1 µg of anti-bovine CD11a or CD18 MAb in FACS buffer (phosphate-buffered saline containing 2% goat serum and 5 mM NaN3) for 15 min on ice. Cells were washed using FACS buffer and incubated with a 1:200 dilution of phycoerythrin-labeled goat anti-mouse secondary antibody (Jackson ImmunoResearch, West Grove, Pa.) in FACS buffer for 15 min on ice. Cells were washed and resuspended in 100 µl of FACS buffer, and fluorescence was analyzed by a FACS Calibur flow cytometry system using CellQuest software (Becton Dickinson Immunocytometry Systems, San Jose, Calif.) and expressed as mean fluorescence intensity. All chimeric CD18 antigens expressed on the cell surfaces of the transductants were recognized by the CD18-specific MAb BAQ30A (Fig. 2). Since studies by others (2, 12) have established unequivocally that the CD11 and CD18 subunits have to associate with each other as a heterodimer to be transported and expressed on the surface of a cell, it is very likely that the various chimeric LFA-1 transductant cells used in the present study express these subunits as a heterodimer.
![]() View larger version (27K): [in a new window] |
FIG. 2. Demonstration of surface expression of bovine CD18 chimeric antigens in various transductants. Surface expression of chimeric CD18 antigens in the various transductants was confirmed by FACS using anti-CD18-specific MAb BAQ30A. The parent cell line K562 cells (open trace) which do not express CD18 antigen were used as a negative control. The x axis shows fluorescence intensity (FL2-H), the y axis shows cell numbers (counts), and the numbers shown within the panels are the percentages of positive CD18 cells. Results show high levels of expression of CD18 antigen in all chimeric transductants (filled traces). Data presented are representative of one of three experiments performed. FL2-H, height for phycoerythrin; M1, marker 1.
|
A modified affinity chromatography assay was used to demonstrate LktA binding to immobilized chimeric CD18. Lysates (6) from the various chimeric LFA-1 transductant cells (1 x 108 cells) were precleared using isotype-matched control MAb (MOPC21) and sequentially depleted of bovine CD11a and residual heterodimers of CD11a/CD18 three times by immunoprecipitation with anti-CD11a MAb R3.1 coupled to Sepharose CL4B beads (Amersham Biosciences, Piscataway, NJ). Depleted lysates were incubated with anti-CD18 MAb BAQ30A coupled to Sepharose CL4B beads to immunoprecipitate the chimeric CD18. The beads bound to the chimeric CD18 were blocked with 1% bovine serum albumin for 1 h and incubated overnight at 4°C with LktA (50 leukotoxin units [LU]/ml) in Hanks balanced salt solution containing 1 mM CaCl2 and MgCl2. The bound LktA was cross-linked with a fresh solution of 1% paraformaldehyde for 10 min to enhance stability. The beads were washed four times with Hanks balanced salt solution, and the bound proteins were eluted from the beads by boiling the beads with 50 µl of Laemmli sample buffer containing ß-mercaptoethanol. Eluted proteins were separated on 4 to 15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gradient gels and subjected to Western blotting. Thereafter, the membrane was incubated with a 1:20,000 dilution of MAb601 (anti-LktA) antibody for 1 h at room temperature, followed by washes and incubation with a 1:50,000 dilution of the appropriate horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. The blots were developed using the SuperSignal ULTRA chemiluminescence detection system (Pierce Chemical Co.). As shown in Fig. 3, LktA binding was demonstrated in chimeric CD18 in transductants B600H, B700H, H110B, H200B, H400B, and H500B but not in the B110H, B200H, B400H, and H600B. These results indicate that LktA binds to a site between amino acid residues 500 and 600 within the bovine CD18 extracellular region.
|
View larger version (14K): [in a new window] |
FIG. 3. Western blot demonstrating binding of LktA to immobilized chimeric CD18 from various transductants. Cell lysates from various transductants were processed as described in the text. The different chimeric CD18s were immunoprecipitated from cell lysates with MAb BAQ30A coupled to Sepharose CL-4B beads and incubated separately with LktA, followed by detection of bound LktA with an anti-LktA MAb. LktA binds to chimeric transductants B600H, B700H, H110B, H200B, H400B, and H500B but not to B110H, B200H, B400H, and H600B. Bovine CD18 immunoprecipitated from BoLFA-1 cell lysate and human CD18 immunoprecipitated from KL/4 cell lysate served as controls. Data shown are from one representative experiment of three experiments performed.
|
50 cells were sampled, and two coverslips were used for each experiment. Significant elevation of [Ca2+]i levels following exposure to LktA (50 LU/ml) was observed in the same transductants that showed binding to LktA, namely, the B600H, B700H, H110B, H200B, H400B, and H500B transductants but not in the B110H, B200H, B400H, and H600B transductants (Fig. 4).
![]() View larger version (19K): [in a new window] |
FIG. 4. LktA induces [Ca2+]i elevation in the B600H, B700H, H110B, H200B, H400B, and H500B but not in the B110H, B200H, B400H, and H600B transductants. Measurement of the [Ca2+]i level was done using the cell-permeable fluorescent dye fura-2/AM ester. The net [Ca2+]i response (peak response subtracted from basal values) was measured as described in the text. Results are expressed as means ± standard errors of the means for three separate experiments. The BoLFA-1 (BoCD11a/BoCD18), KL/4 line (HuLFA-1; HuCD11a/HuCD18), and parent K562 cell transductants served as controls. Values that are significantly different from the negative control value (P < 0.05) are indicated by asterisks.
|
![]() View larger version (23K): [in a new window] |
FIG. 5. LktA-induced cytolysis in the chimeric transductants. Cytolysis of various cell lines exposed to 100 units of LktA (100 LU/ml) was measured by the XTT assay as described in the text. Transductants B600H, B700H, H110B, H200B, H400B, and H500B showed marked cytotoxicity compared to that obtained with the parent cell line. By contrast, transductants B110H, B200H, B400H, and H600B showed lower cytotoxicity upon exposure to LktA, comparable to that obtained with parent cell line. The BoLFA-1 (BoCD11a/BoCD18), KL/4 line (HuLFA-1, HuCD11a/HuCD18), and parent K562 cell transductants served as controls. Results are expressed as means ± standard errors of the means for three separate experiments. Values that are significantly different from the negative control value (P < 0.05) are indicated by asterisks.
|
|
|
|---|
B activation and calcium elevation. Microb. Pathog. 26:263-273.[CrossRef][Medline]
subunit. Proc. Natl. Acad. Sci. USA 94:3156-3161.
This article has been cited by other articles:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»